World Diabetes Day: 14 November 2012
The European Medicines Agency supports World Diabetes Day, which is taking place on Wednesday 14 November 2012.
World Diabetes Day is held each year on 14 November and is dedicated to engaging people worldwide in diabetes advocacy and awareness. For the period 2009-2013, the day's theme is diabetes education and prevention.
The Agency plays an important role in the authorisation of medicines to treat diabetes. The Agency considers the development of medicines for diabetes to be an important issue because of the extent of the disease and its growth, particularly type-2 diabetes.
In the European Union (EU), all medicines for diabetes must be authorised via the Agency, rather than in each Member State individually. To date, more than 40 medicines for use in diabetic patients have been authorised on the recommendation of the Agency. These include two important recommendations for novel diabetes treatments over the past year, including a first-in-class medicine for type-2 diabetes recommended in April and the first high-strength insulin-containing medicine, which the Agency recommended for authorisation in October.
The Agency stimulates research into medicines for diabetes in all age groups, including children. In June this year, the Agency updated its guidance on the treatment and prevention of diabetes. The main change involved revision of the information on the long-term safety of antidiabetes medicines and the inclusion of more specific and up-to-date information on studies in children.
The Agency works closely with organisations representing patients with diabetes through the Insulin Dependent Diabetes Trust and the International Diabetes Federation and with organisations representing healthcare professionals in the diabetes field through the European Association for the Study of Diabetes.
To explore the medicines authorised for diabetes patients on the recommendation of the Agency, browse the European public assessment reports by therapeutic area or keyword.
Related News
-
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News A Day in the Life of a President and Chief Scientific Officer
We are continuing to get to know the people working day-to-day behind the pharma companies shaping the industry, the ones who keep the wheels turning and ultimately bring better healthcare to the population; we are talking to the individuals at the hea... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News LEAP-ing into the future of pharma – the CPHI Middle East Vision
On March 6, 2024, the CPHI team hosted the Future of Pharma Forum at LEAP 2024, Saudi Arabia’s premier destination for tech leaders and innovators to meet and collaborate. -
News Informa Markets International Women’s Day Panel Discussion
On March 7, 2024, the Informa Markets Amsterdam office hosted an International Women’s Day Breakfast and Panel Discussion to celebrate the women who drive the B2B events industry forward, including members of the CPHI team. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance